HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy
Authors:
Julie Vanderpoel
Julie VanderpoelJanssen Scientific Affairs, Horsham, PA